BioAge Shares Slide Premarket After Obesity Study Halted for Safety

Dow Jones

Dec 09, 2024

By Colin Kellaher

Shares of BioAge Labs plunged nearly 70% in premarket trading Monday after the clinical-stage biopharmaceutical company said it was ending a mid-stage study of its lead program, a proposed obesity drug, due to safety concerns.

After the closing bell on Friday, BioAge said it is discontinuing a Phase 2 study of azelaprag after some participants developed liver transaminitis, a condition where the levels of liver enzymes in the blood are higher than normal.

The Richmond, Calif., company said it is assessing its next steps for the azelaprag program, adding that it will continue to advance its earlier-stage programs.

On the heels of the news, Citi downgraded BioAge's shares to neutral from buy and slashed its price target on the stock to $7 from $45.

In a research note, Citi analysts Samantha Semenkow and Geoff Meacham said they believe the liver signal limits azelaprag's path forward in obesity, and that they see limited near-term upside for the stock.

However, Citi said BioAge's pipeline, discovery platform and cash runway to at least 2029 have the potential to be longer-term tailwinds.

BioAge shares, which closed Friday at $20.09, were recently down 69% at $6.15 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 09, 2024 06:28 ET (11:28 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2490282157"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490282157\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2490282157?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-09 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490282157","market":"sh","top_or_hot":-1,"title":"BioAge Shares Slide Premarket After Obesity Study Halted for Safety","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of BioAge Labs plunged nearly 70% in premarket trading Monday after the clinical-stage biopharmaceutical company said it was ending a mid-stage study of its lead program, a proposed obesity drug, due to safety concerns. \n</p>\n<p>\n  After the closing bell on Friday, BioAge said it is discontinuing a Phase 2 study of azelaprag after some participants developed liver transaminitis, a condition where the levels of liver enzymes in the blood are higher than normal. \n</p>\n<p>\n  The Richmond, Calif., company said it is assessing its next steps for the azelaprag program, adding that it will continue to advance its earlier-stage programs. \n</p>\n<p>\n  On the heels of the news, Citi downgraded BioAge's shares to neutral from buy and slashed its price target on the stock to $7 from $45. \n</p>\n<p>\n  In a research note, Citi analysts Samantha Semenkow and Geoff Meacham said they believe the liver signal limits azelaprag's path forward in obesity, and that they see limited near-term upside for the stock. \n</p>\n<p>\n  However, Citi said BioAge's pipeline, discovery platform and cash runway to at least 2029 have the potential to be longer-term tailwinds. \n</p>\n<p>\n  BioAge shares, which closed Friday at $20.09, were recently down 69% at $6.15 in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 09, 2024 06:28 ET (11:28 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioAge Shares Slide Premarket After Obesity Study Halted for Safety</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioAge Shares Slide Premarket After Obesity Study Halted for Safety\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-09 19:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of BioAge Labs plunged nearly 70% in premarket trading Monday after the clinical-stage biopharmaceutical company said it was ending a mid-stage study of its lead program, a proposed obesity drug, due to safety concerns. \n</p>\n<p>\n  After the closing bell on Friday, BioAge said it is discontinuing a Phase 2 study of azelaprag after some participants developed liver transaminitis, a condition where the levels of liver enzymes in the blood are higher than normal. \n</p>\n<p>\n  The Richmond, Calif., company said it is assessing its next steps for the azelaprag program, adding that it will continue to advance its earlier-stage programs. \n</p>\n<p>\n  On the heels of the news, Citi downgraded BioAge's shares to neutral from buy and slashed its price target on the stock to $7 from $45. \n</p>\n<p>\n  In a research note, Citi analysts Samantha Semenkow and Geoff Meacham said they believe the liver signal limits azelaprag's path forward in obesity, and that they see limited near-term upside for the stock. \n</p>\n<p>\n  However, Citi said BioAge's pipeline, discovery platform and cash runway to at least 2029 have the potential to be longer-term tailwinds. \n</p>\n<p>\n  BioAge shares, which closed Friday at $20.09, were recently down 69% at $6.15 in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 09, 2024 06:28 ET (11:28 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIOA","symbol_name":"BioAge Labs Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490282157","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490282157","pubTimestamp":1733743680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of BioAge Labs plunged nearly 70% in premarket trading Monday after the clinical-stage biopharmaceutical company said it was ending a mid-stage study of its lead program, a proposed obesity drug, due to safety concerns.After the closing bell on Friday, BioAge said it is discontinuing a Phase 2 study of azelaprag after some participants developed liver transaminitis, a condition where the levels of liver enzymes in the blood are higher than normal.The Richmond, Calif., company said it is assessing its next steps for the azelaprag program, adding that it will continue to advance its earlier-stage programs.On the heels of the news, Citi downgraded BioAge's shares to neutral from buy and slashed its price target on the stock to $7 from $45.In a research note, Citi analysts Samantha Semenkow and Geoff Meacham said they believe the liver signal limits azelaprag's path forward in obesity, and that they see limited near-term upside for the stock.However, Citi said BioAge's pipeline, dis","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIOA":"BioAge Labs Inc.","BK4007":"制药"},"translate_title":"肥胖研究因安全原因停止后，BioAge股价盘前下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIOA":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Shares of BioAge Labs plunged nearly 70% in premarket trading Monday after the clinical-stage biopharmaceutical company said it was ending a mid-stage study of its lead program, a proposed obesity drug, due to safety concerns. \n\n\n  After the closing bell on Friday, BioAge said it is discontinuing a Phase 2 study of azelaprag after some participants developed liver transaminitis, a condition where the levels of liver enzymes in the blood are higher than normal. \n\n\n  The Richmond, Calif., company said it is assessing its next steps for the azelaprag program, adding that it will continue to advance its earlier-stage programs. \n\n\n  On the heels of the news, Citi downgraded BioAge's shares to neutral from buy and slashed its price target on the stock to $7 from $45. \n\n\n  In a research note, Citi analysts Samantha Semenkow and Geoff Meacham said they believe the liver signal limits azelaprag's path forward in obesity, and that they see limited near-term upside for the stock. \n\n\n  However, Citi said BioAge's pipeline, discovery platform and cash runway to at least 2029 have the potential to be longer-term tailwinds. \n\n\n  BioAge shares, which closed Friday at $20.09, were recently down 69% at $6.15 in premarket trading. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2024 06:28 ET (11:28 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}